70 results about "Oxygen affinity" patented technology

The present invention relates to blood products, and more particularly to compositions comprising a modified oxygenated hemoglobin having a high affinity for oxygen and methods for making such compositions. Such compositions according to the present invention have better stability to autooxidation and superior oxygen carrying characteristics.

The invention discloses manganese-cerium composite oxide, which is prepared in one step through the oxidation reduction-precipitation process among Mn<VII>, Mn<II> and Ce<III> ions, wherein components, namely MnO2 and CeO2 of the manganese-cerium composite oxide have high dispersion on a near molecular scale, the mol ratio of Mn to Ce is randomly adjusted, and the composite oxide has good oxidation reduction and oxygen affinity. As a catalyst carrier of reactions of formaldehyde oxidation at room temperature and low-temperature selective catalytic reduction of nitrogen oxide, the use of the composite oxide can ensure that a catalyst has higher activity, and the stability of the composite oxide is more superior to those of other carriers.

A composite magnetic material includes metal magnetic powder and thermosetting resin. The metal magnetic powder includes first metal magnetic powder and second metal magnetic powder. The first metal magnetic powder includes iron and a first element with oxygen affinity higher than that of iron. The second metal magnetic powder includes at least iron. The second metal magnetic powder also includes the first element for an amount smaller than the first element contained in the first metal magnetic powder, or not include the first element. A mean particle diameter of the first metal magnetic powder is greater than a mean particle diameter of the second metal magnetic powder. The second metal magnetic powder is 10 weight % to 30 weight % of the total amount of the metal magnetic powder. This composite magnetic material can secure high magnetic permeability and also improve withstand voltage.

A lead-free solder comprises an alloy of silver and bismuth in amounts of 2wt% to 18wt% and 98wt% to 82wt%, respectively. Contemplated alloys have a solidus of no lower than 262.5 deg.C and a liquidus of no higher than 400 deg.C. Contemplated alloys may further comprise a chemical element with an oxygen affinity that is higher than the oxygen affinity of the alloy.

Integrated circuit electrodes include an alloy of a first metal and a second metal having lower work function than the first metal. The second metal also may have higher oxygen affinity than the first metal. The first metal may be Ru, Ir, Os, Re and alloys thereof, and the second metal may be Ta, Nb, Al, Hf, Zr, La and alloys thereof. Both NMOS and the PMOS devices can include gate electrodes of an alloy of the first metal and the second metal having lower work function than the first metal. The PMOS gate electrode may have a higher percentage of the first metal relative to the second metal than the NMOS gate electrode. Thus, a common material system may be used for gate electrodes for both NMOS and PMOS devices.

Methods for preparation of a heat stable hemoglobin based oxygen-carrier-containing pharmaceutical composition such that beta-beta cross-linking is favored are provided. Using the methods of the present invention, the oxygen affinity of the resultant molecule can be controlled so that hemoglobin based oxygen carriers tailored for specific applications can be produced. Lower oxygen affinity crosslinked hemoglobin is useful for applications requiring rapid tissue oxygenation (e.g. hemorrhagic shock) while higher oxygen affinity cross-linked hemoglobin is useful for applications requiring a slower rate of oxygenation (e.g. cancer adjunct therapy). A highly purified and heat stable crosslinked non-polymeric tetrameric hemoglobin having beta-beta cross-linking of greater than 40-60% and suitable for use in mammals without causing renal injury and vasoconstriction is produced. A high temperature and short time (HTST) heat processing step is performed to effectively remove any undesired dimeric hemoglobin, non-crosslinked tetrameric hemoglobin, and plasma protein impurities.

The invention belongs to a biodegradable nano-particle bonded with a hemoglobin molecule, and a method for preparing the biodegradable nano-particle. A polyethylene glycol polyester copolymer with such active functional groups as carboxy groups, amino groups, hydroxyl groups, triple bonds and so on in lateral chains is assembled to form micelle, and the micelle is bonded with the hemoglobin molecule; or firstly, the polyethylene glycol polyester copolymer is bonded with the hemoglobin molecule and then is assembled to get a chemical bonded hemoglobin nano-particle system. The size of the nano-particle prepared ranges from 80nm to 800nm. The hemoglobin accounts for 100 to 500 percent of the nano-particle by weight; the viscosity of the solution ranges from 1MPs to 4MPs; the salt content ranges from 50mM to 200mM; the pH value ranges from 7.0 to 7.6; the oxygen Affinity ranges from 6mmHg to 50mmHg; the stable half life of the hemoglobin ranges from 15 to 24 hours. The bonded hemoglobin nano-particle can be used for manual transmission of oxygen, and as an erythrocyte simulator, which can be used for clinical blood transfusion and to cure cardiovascular and cerebrovascular diseases.

Inositol-tripyrophosphate is an allosteric effector of hemoglobin due to its ability to cross the plasma membrane of red blood cells and deliver oxygen to solid tumors, by lowering the oxygen affinity of the hemoglobin of red blood cells. The present invention is directed to the use of inositol-tripyrophosphate to reduce hemoglobin's affinity for oxygen in circulating red blood cells. The present invention is further directed to the use of inositol-tripyrophosphate to inhibit angiogenesis and enhance radiation sensitivity of hypoxic tumors. The present invention is further directed to the use of inositol-tripyrophosphate for the treatment of various types of cancers, Alzheimer's disease, stroke and osteoporosis.

Inositol-tripyrophosphate is an allosteric effector of hemoglobin due to its ability to cross the plasma membrane of red blood cells and deliver oxygen to solid tumors, by lowering the oxygen affinity of the hemoglobin of red blood cells. The present invention is directed to the use of inositol-tripyrophosphate to reduce hemoglobin's affinity for oxygen in circulating red blood cells. The present invention is further directed to the use of inositol-tripyrophosphate to inhibit angiogenesis and enhance radiation sensitivity of hypoxic tumors. The present invention is further directed to the use of inositol-tripyrophosphate to enhance PO2 in hypoxic tumors.

The invention relates to a supported non-metal catalyst, a preparation method and an application of the catalyst in catalyzing oxidative dehydrogenation of low-carbon alkanes. The supported non-metalcatalyst comprises a boron oxide and silicon oxide, wherein the boron oxide is supported on the silicon oxide, the boron oxide accounts for 0.1-30% by mass. The supported non-metal catalyst provided by the invention is prepared by a simple preparation method, takes porous silicon oxide with weak surface acidity as a carrier, has highly dispersed active sites (tri-coordinated boron oxide species),and does not easily catalyze deep oxidation of olefins. B-O-Si bonds formed by roasting fixedly support the active boron species, so that the active components of the catalyst are not easy to lose andthe catalyst has good stability. In the catalysis of oxidative dehydrogenation of low-carbon alkanes, the catalyst leads to high conversion of alkanes and olefin yields at a lower temperature (400 DEG C) due to the rich active tri-coordinated boron oxide species and the oxygen-affinity of boron sites of the catalyst, and the amount of CO2 generated can be neglected.

The invention discloses a hemoglobin-based oxygen carrier wrapped by polydopamine as well as a preparation method and applications of the hemoglobin-based oxygen carrier. The hemoglobin-based oxygen carrier is obtained by wrapping hemoglobin by adopting polydopamine. Specifically, the preparation method comprises the following steps: mixing hemoglobin stock solution and dopamine solution, and carrying out polymerization reaction of dopamine and the loading reaction of wrapping hemoglobin by adopting polydopamine, thus obtaining the hemoglobin-based oxygen carrier wrapped by polydopamine. The oxygen carrier provided by the invention belongs to the nanoscale, and is free of the agglomeration phenomenon; hemolysis can not be caused, and the cytotoxicity can not be caused; the chemical constitution and secondary structure of hemoglobin can not be damaged, and thus the normal exertion of the physiological function of hemoglobin is guaranteed; the oxygen loading and release can be effectively realized, the oxygen affinity is high, meanwhile, the oxidation resistance is good, the auto-oxidation of hemoglobin can be effectively inhibited, the various free radicals and active oxygen in red blood cells can be eliminated, and the problem that the existing hemoglobin carriers easily have oxidative damage is solved. The preparation process is simple, the consumed time is short, and the method is suitable for large-scale production.

A solder joint material includes a copper-based metal material including mainly a copper, a surface-treated layer that is provided on the copper-based metal material and includes an amorphous layer including oxygen and a metal with a higher oxygen affinity than a copper, and a Sn-based solder plating layer provided on the surface-treated layer.

An anode body for a capacitor and method for producing the same, which method includes compressing a powder mixture containing a tungsten powder and a high-oxygen-affinity metal powder into a compact with a wire rod planted therein, and firing the compact into a sintered compact. The high-oxygen-affinity metal has an oxygen affinity higher than that of tungsten. The content of the high-oxygen-affinity metal powder in the powder mixture is regulated so that the content of the high-oxygen-affinity metal in the sintered compact is 0.1 to 3% by mass based on the mass of the tungsten in the sintered compact. The wire rod includes tantalum or niobium. Also disclosed is an electrolytic capacitor including the anode body.

The present disclosure relates to a semiconductor device including an oxygen gettering layer between a group III-V compound semiconductor layer and a dielectric layer, and a method of fabricating the semiconductor device. The semiconductor device may include a compound semiconductor layer; a dielectric layer disposed on the compound semiconductor layer; and an oxygen gettering layer interposed between the compound semiconductor layer and the dielectric layer. The oxygen gettering layer includes a material having a higher oxygen affinity than a material of the compound semiconductor layer.

Compounds for the treatment of sickle-cell disease, and methods for their use are provided. The compounds have a dual mode of action. First, binding of the compounds to hemoglobin increases the oxygen affinity of both normal and sickle hemoglobin. Secondly, binding of these compounds to the N-terminal amino acid of sickle hemoglobin results in destabilization of potential contacts between sickle hemoglobin molecules, preventing polymerization and the formation of fibrous precipitates of the sickle hemoglobin. The compounds are also useful for inducing hypoxia, e.g. to augment cancer treatments.

A copper foil includes a copper-based metal sheet including mainly a copper, and a surface-treated layer that is provided on the copper-based metal sheet and includes an amorphous layer including oxygen and a metal with a higher oxygen affinity than a copper. A total thickness of the copper-based metal sheet and the surface-treated layer is less than 0.55 mm.

Compounds for the treatment of sickle-cell disease, and methods for their use are provided. The compounds have a dual mode of action. First, binding of the compounds to hemoglobin increases the oxygen affinity of both normal and sickle hemoglobin. Secondly, binding of these compounds to the N-terminal amino acid of sickle hemoglobin results in destabilization of potential contacts between sickle hemoglobin molecules, preventing polymerization and the formation of fibrous precipitates of the sickle hemoglobin. The compounds are also useful for inducing hypoxia, e.g. to augment cancer treatments.

Methods for preparation of a heat stable hemoglobin based oxygen-carrier-containing pharmaceutical composition such that beta-beta cross-linking is favored are provided. Using the methods of the present invention, the oxygen affinity of the resultant molecule can be controlled so that hemoglobin based oxygen carriers tailored for specific applications can be produced. Lower oxygen affinity crosslinked hemoglobin is useful for applications requiring rapid tissue oxygenation (e.g. hemorrhagic shock) while higher oxygen affinity cross-linked hemoglobin is useful for applications requiring a slower rate of oxygenation (e.g. cancer adjunct therapy). A highly purified and heat stable crosslinked non-polymeric tetrameric hemoglobin having beta-beta cross-linking of greater than 40-60% and suitable for use in mammals without causing renal injury and vasoconstriction is produced. A high temperature and short time (HTST) heat processing step is performed to effectively remove any undesired dimeric hemoglobin, non-crosslinked tetrameric hemoglobin, and plasma protein impurities.

A solder joint material includes a Zn-based metal material including mainly of Zn, an Al-based metal material including mainly of Al and provided on the Zn-based metal material, a Cu-based metal material including mainly of Cu and provided on the Al-based metal material, and a surface-treated layer provided on the Cu-based metal material and including an amorphous layer including oxygen and a metal with a higher oxygen affinity than a copper.

A lead-free solder comprises an alloy of silver and bismuth in amounts of about 2 wt% to about 18 wt% and about 98 wt% to about 82 wt%, respectively. Contemplated alloys further comprise at least one of zinc, nickel, germanium or a combination thereof in an amount of up to about 1000 ppm (preferably about 500ppm) and have a solidus of no lower than about 262.5 DEG C and a liquidus of no higher than about 400 DEG C. Contemplated alloys may further comprise a chemical element with an oxygen affinity that is higher than the oxygen affinity of at least one of the constituents of the alloy, and particularly contemplated elements are phosphorus and germanium.

Inositol-tripyrophosphate is an allosteric effector of hemoglobin due to its ability to cross the plasma membrane of red blood cells and deliver oxygen to solid tumors, by lowering the oxygen affinity of the hemoglobin of red blood cells. The present invention is directed to the use of inositol-tripyrophosphate to reduce hemoglobin's affinity for oxygen in circulating red blood cells. The present invention is further directed to the use of inositol-tripyrophosphate to inhibit angiogenesis and enhance radiation sensitivity of hypoxic tumors. The present invention is further directed to the use of inositol-tripyrophosphate to enhance PO2 in hypoxic tumors.

A refractory alloy that includes rhenium as the most abundant alloy component by atomic percent includes tungsten, and at least one element having a higher oxygen affinity than rhenium and having a melting temperature of at least 1650° C. One exemplary alloy includes at least 90% rhenium by atomic percent, about 0.25% to about 4% tungsten by atomic percent, and about 0.25% to about 2% tantalum by atomic percent.

Disclosed herein are processes for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H- pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde (also referred to herein as Compound (I)) and intermediates used in such processes. Compound (I) binds to hemoglobin and increases it oxygen affinity and hence can be useful for the treatment of diseases such as sickle cell disease.

The invention discloses hemoglobin oxygen carrier-PEG-PLGA encapsulated hemoglobin. The PEG-PLGA encapsulated hemoglobin is obtained by encapsulating the hemoglobin with polyethylene glycol-poly(lactide-co-glycolide) (PEG-PLGA) nanoparticles. The hemoglobin is uniform in particle size distribution, good in dispersibility and high in oxygen appetency and has good oxygen supply effect and can be used for the system with general or partial anoxia or the system needing in vitro oxygen supply. The hemoglobin oxygen carrier-PEG-PLGA encapsulated hemoglobin plays an important role in the medical field when serving as a blood substitute and has a broad application prospect.

The invention discloses a method for synergistically and deeply removing oxygen in metal titanium by super-oxyphilic metal and calcium. The method comprises the following steps: filling specific positions of a reactor with materials such as super-oxyphilic metal, anhydrous calcium chloride, a titanium raw material and a calcium reducing agent; and carrying out distillation-deoxidation and disassembly-cleaning so as to stably reduce the oxygen content of titanium to be smaller than 100 ppm. The super-oxyphilic metal has extremely high oxygen affinity, and oxygen in calcium chloride fused salt can be subjected to solid solution or forms oxide, so that extremely low oxygen potential is created, and the thermodynamic problem of deep deoxidation is solved; and the calcium chloride fused salt has high fluidity and high solubility to the calcium reducing agent and calcium oxide, so that the kinetics problem of deoxidation is solved. Through organic combination of purification and deoxidationof Ca, deep, efficient and stable removal of oxygen in the metal titanium is realized. The method disclosed by the invention is simple and easy to implement, good in oxygen removal effect and free ofsecondary pollution, and the product meets the use requirements in the fields of target material manufacturing, optical coating, electronic element manufacturing and the like.

An object is to provide a secondary battery having excellent charge-discharge cycle characteristics. A secondary battery including an electrode containing silicon or a silicon compound is provided, in which the electrode is provided with a layer containing silicon or a silicon compound over a layer of a metal material; a mixed layer of the metal material and the silicon is provided between the metal material layer and the layer containing silicon or a silicon compound; the metal material has higher oxygen affinity than that of ions which give and receive electric charges in the secondary battery; and an oxide of the metal material does not have an insulating property. The ions which give and receive electric charges are alkali metal ions or alkaline earth metal ions.